

October 27, 2009



SCYNEXIS Receives Milestone Payment in Oncology Collaboration with Merck & Co., Inc.

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- Drug discovery company SCYNEXIS, Inc. today announced that it has received a payment from Merck & Co., Inc. for achieving a preclinical milestone resulting from a collaboration to discover and develop novel oncology agents.

"We are pleased to celebrate success in reaching another milestone with our valued partner, Merck," said Yves Ribeill, Ph.D., President and Chief Executive Officer of SCYNEXIS. "This milestone provides further validation of our long-term relationship with Merck in a number of therapeutic areas through discovery research and innovation."

About SCYNEXIS

SCYNEXIS is a premier drug discovery and development company headquartered in Research Triangle Park, North Carolina. SCYNEXIS' mission is to be the leader in delivering effective and innovative drug pipeline solutions to its pharmaceutical partners.

SCYNEXIS research teams integrate medicinal chemistry, advanced biological screening, computational chemistry, bioanalysis and analytical chemistry and use powerful, proprietary technologies such as the HEOS(R) Software Suite and MEDCHEM-FACTORY(R) to advance molecules to candidate selection. SCYNEXIS development teams have been tailored to be especially effective in moving customer projects from the discovery phase to the clinic. SCYNEXIS process chemistry and bioanalytical departments operate under current GMP/GLP guidelines and have a strong track record of success. SCYNEXIS is registered with both the FDA and DEA. www.scynexis.com

Source: SCYNEXIS, Inc.